Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday

Adial Pharmaceuticals (NASDAQ:ADIL) will likely be announcing its results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

Adial Pharmaceuticals Price Performance

Shares of ADIL opened at $2.53 on Friday. The business’s fifty day moving average is $4.68 and its 200 day moving average is $7.25. Adial Pharmaceuticals has a 12-month low of $2.27 and a 12-month high of $30.25. The stock has a market cap of $2.81 million, a P/E ratio of -0.13 and a beta of 1.26.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ADIL. UBS Group set a $8.00 price objective on shares of Adial Pharmaceuticals in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $22.75.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Armistice Capital LLC bought a new stake in Adial Pharmaceuticals in the 4th quarter worth about $562,000. Jane Street Group LLC boosted its stake in shares of Adial Pharmaceuticals by 887.3% in the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after buying an additional 109,500 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Adial Pharmaceuticals in the 3rd quarter worth approximately $51,000. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.